Association between voriconazole exposure and Sequential Organ Failure Assessment (SOFA) score in critically ill patients
暂无分享,去创建一个
T. Rimmele | L. Argaud | S. Goutelle | P. Pradat | V. Piriou | C. Chidiac | J. Fellahi | A. Bienvenu | F. Parant | M. Tod | J. Menotti | M. Gagnieu | G. Leboucher | F. Aubrun | J. Richard | V. Leclerc | A. Pleşa
[1] J. Perfect,et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance , 2020, The Lancet Infectious Diseases.
[2] J. Perfect,et al. Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. , 2020, The Journal of infectious diseases.
[3] M. Neuenhahn,et al. Invasive pulmonary aspergillosis in critically ill patients with severe COVID-19 pneumonia: Results from the prospective AspCOVID-19 study , 2020, medRxiv.
[4] Qi Li,et al. Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy , 2020, Basic & clinical pharmacology & toxicology.
[5] H. Ikeuchi,et al. Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: A multicentre study conducted in Japan , 2020, Mycoses.
[6] D. Marriott,et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper# , 2020, Intensive Care Medicine.
[7] P. Escribano,et al. Therapeutic Drug Monitoring of Antifungal Drugs: Another Tool to Improve Patient Outcome? , 2020, Infectious Diseases and Therapy.
[8] Á. Castellanos-Ortega,et al. Impact of voriconazole plasma concentrations on treatment response in critically ill patients , 2019, Journal of clinical pharmacy and therapeutics.
[9] D. Wiebe,et al. Impact of Triazole Therapeutic Drug Monitoring Availability and Timing , 2019, Antimicrobial Agents and Chemotherapy.
[10] J. Timsit,et al. Intensive care medicine research agenda on invasive fungal infection in critically ill patients , 2017, Intensive Care Medicine.
[11] Y. Nannya,et al. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. , 2016, The Journal of antimicrobial chemotherapy.
[12] J. Xing,et al. Risk Factors for Voriconazole‐Associated Hepatotoxicity in Patients in the Intensive Care Unit , 2016, Pharmacotherapy.
[13] S. Zhai,et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis , 2016, The Journal of antimicrobial chemotherapy.
[14] P. G. Choe,et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] F. Farowski,et al. Therapeutic Drug Monitoring of Voriconazole and Posaconazole , 2011, Pharmacotherapy.
[16] S. Markantonis,et al. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study. , 2010, International journal of antimicrobial agents.
[17] F. Tacke,et al. Liver — guardian, modifier and target of sepsis , 2017, Nature Reviews Gastroenterology &Hepatology.